Physician profile
Amanda L Springer
NPI 1144660838
$1,205.02
in general payments reported to CMS, 2019-2025
21 companies · $47.01 in 2025
The $47.01 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2020: $92.42 · 2021: $233 · 2022: $274 · 2023: $256 · 2024: $77.79 · 2025: $47.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $381.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $205.65 | 2021-2024 | Vraylar |
| Glaxosmithkline, LLC. | $169.71 | 2019-2025 | Trelegy Ellipta |
| Amgen INC. | $150.18 | 2019-2023 | Prolia, Evenity, Otezla |
| Pfizer INC. | $139.94 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $96.94 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $83.07 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $72.18 | 2019-2022 | |
| Inspire Medical Systems, INC. | $54.98 | 2023-2024 | Inspire |
| Esperion Therapeutics, INC. | $43.02 | 2020-2023 | Nexletol |
| Novo Nordisk INC | $37.98 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $21.56 | 2022 | |
| Astellas Pharma US INC | $21.08 | 2023 | Veozah |
| Boston Scientific Corporation | $17.23 | 2025 | Watchman Flx |
| Vifor Pharma, INC. | $16.16 | 2019 | |
| Lilly USA, LLC | $13.47 | 2023 | Trulicity, Mounjaro |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $13.32 | 2019 | |
| Dexcom, INC. | $12.90 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $11.93 | 2019 | |
| Merck Sharp & Dohme LLC | $11.53 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.20 | 2019 | |
| Allergan, INC. | $0.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Springer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.